Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis.

Adult Antibodies, Viral Ebola Vaccines / adverse effects Ebolavirus Hemorrhagic Fever, Ebola / epidemiology Humans Network Meta-Analysis Randomized Controlled Trials as Topic
Ebolavirus healthy volunteer network meta-analysis vaccine

Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
03 10 2021
Historique:
pubmed: 17 7 2021
medline: 26 10 2021
entrez: 16 7 2021
Statut: ppublish

Résumé

Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety. A total of 21 randomized controlled trial, evaluating seven different vaccines with different doses, and 5,275 participants were analyzed. The rVSVΔG-ZEBOV-GP (2 × 10

Identifiants

DOI: 10.1080/21645515.2021.1932214 PMID: 34270366 PMC: PMC8437548
pubmed: 34270366
doi: 10.1080/21645515.2021.1932214
pmc: PMC8437548
doi:

Substances chimiques

Antibodies, Viral 0
Ebola Vaccines 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3771-3783

Références

J Infect Dis. 2019 Jun 5;220(1):46-56
pubmed: 30796818
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
PLoS Med. 2017 Oct 6;14(10):e1002402
pubmed: 28985239
Expert Rev Vaccines. 2016 Sep;15(9):1101-12
pubmed: 27160784
J Infect Dis. 2019 Aug 30;220(7):1127-1135
pubmed: 31505665
Lancet Infect Dis. 2016 Jan;16(1):31-42
pubmed: 26546548
J Infect Dis. 2017 Jun 15;215(12):1789-1798
pubmed: 28549145
Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168
pubmed: 27764560
CMAJ. 2017 Jun 19;189(24):E819-E827
pubmed: 28630358
Int J Epidemiol. 2002 Feb;31(1):115-23
pubmed: 11914306
Lancet Glob Health. 2017 Mar;5(3):e324-e334
pubmed: 28017642
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
Lancet Infect Dis. 2020 Apr;20(4):455-466
pubmed: 31952923
Cell. 2016 Nov 3;167(4):1079-1087.e5
pubmed: 27814505
PLoS One. 2020 Oct 29;15(10):e0241016
pubmed: 33119638
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Lancet. 2015 Jun 6;385(9984):2272-9
pubmed: 25817373
J Infect Dis. 2019 Jun 5;220(1):57-67
pubmed: 30796816
Lancet Infect Dis. 2016 Mar;16(3):311-20
pubmed: 26725450
Lancet Infect Dis. 2017 Aug;17(8):854-866
pubmed: 28606591
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Lancet Infect Dis. 2015 Oct;15(10):1156-1166
pubmed: 26248510
Lancet. 2017 Feb 11;389(10069):621-628
pubmed: 28017399
Clin Vaccine Immunol. 2006 Nov;13(11):1267-77
pubmed: 16988008
J Infect Dis. 2018 May 18;217(suppl_1):S6-S15
pubmed: 29788345
N Engl J Med. 2017 Jan 26;376(4):330-341
pubmed: 25830322
Vaccine. 2010 Dec 16;29(2):304-13
pubmed: 21034824
Lancet. 2015 Apr 18;385(9977):1545-54
pubmed: 25540891

Auteurs

Alhassane Diallo (A)

CIC-EC 1425, Department of Epidemiology, Biostatistics, Clinical Research, AP-HP Hospital Bichat, University of Paris Diderot, Paris, France.
ORCID: 0000-0002-1666-8641

Miguel Carlos-Bolumbu (M)

Département d'Urgence-Réanimation, Centre Hospitalier Sud-Essones CHSE, Paris, France.

Minerva Cervantes-Gonzalez (M)

CIC-EC 1425, Department of Epidemiology, Biostatistics, Clinical Research, AP-HP Hospital Bichat, Paris, France.

Veronika Wozniak (V)

Faculty of Medicine, University Paris Diderot, Paris, France.

Mamadou Hassimiou Diallo (MH)

Centre population et développement, Institut de recherche pour le développement, Université Paris Descartes, Paris, France.

Boubacar Djelo Diallo (BD)

Faculté des Sciences et Techniques de la Santé, Université Gamal Abdel Nasser de Conakry, Service de Pneumo-Phtisiologie, CHU Conakry, Hôpital National Ignace Deen de Conakry, Conakry, Guinea.

Alexandre Delamou (A)

Gamal Abdel Nasser University, Conakry, Guinea.

Florence Galtier (F)

INSERM, CIC 1411, CHU of Montpellier, Saint Eloi Hospital, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la maladie à virus Ebola › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Filoviridae › Ebolavirus › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Mononegavirales › Infections à Filoviridae › Fièvre hémorragique à virus Ebola › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méta-analyse comme sujet › Méta-analyse en réseau › Immunogenicity and safety of Ebola virus...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Immunogenicity and safety of Ebola virus...